Compare ARK Genomic Revolution ETF (ARKG) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kohl's Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Kohl's Corporation trades at $16.87 (market cap $1.91B). The key difference: Kohl's Corporation pays a 2.98% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kohl's Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | KSS | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $24.71 |
52-Week Low | $23.09 | $9.27 |
Market Cap | — | $1.91B |
Enterprise Value | — | $8.01B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Kohl's (KSS) trades at $16.80, up 3.0% today, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten expectations, with Q1 2026 showing early turnaround progress, but revenue has declined from $19.4B in 2022 to $16.2B in 2025. The stock is undervalued with a P/E of 7.06 and P/B of 0.47, while analyst sentiment is cautious with a consensus price target of $16.75.
The outlook hinges on Kohl's ability to stabilize sales through proprietary brands and cost controls, but risks include persistent revenue declines and competitive pressures. Upside potential exists if turnaround efforts gain traction, yet investor caution is warranted given weak technicals and mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
